Market Alert: Ukraine Conflict Update and U.S. Policy Risk
ReNerve Limited (ASX: RNV) announced highly positive results from a comparative study evaluating its NervAlign Nerve Cuff. The study demonstrated significant reductions in post-surgery pain and improved patient satisfaction for those treated with the Nerve Cuff. Patients who received the NervAlign Nerve Cuff reported a mean post-operative pain score decrease from 7.1 to 0.4, compared to a reduction from 7.1 to 3.3 in patients without the device.
Moreover, 93% of patients treated with the Nerve Cuff indicated they would undergo the surgery again, compared to 70% without it. The NervAlign Nerve Cuff supports optimal nerve regeneration post-surgery, naturally absorbing within six months to prevent long-term complications. These results reinforce the device’s effectiveness in enhancing nerve repair outcomes, reducing patient discomfort, and improving overall surgical success, marking a significant milestone in ReNerve’s medical innovations.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Aug 27, 2025
Aug 27, 2025
Aug 27, 2025
Aug 27, 2025
Aug 27, 2025
Aug 27, 2025
Aug 27, 2025
Aug 27, 2025
Aug 27, 2025
Aug 27, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
